Therapeutic Candidate or Device CNS10-NPC-GDNF - a neural progenitor cell secreting GDNF Indication Amyotrophic Lateral Sclerosis (ALS) Therapeutic Mechanism This therapy will replace damaged astrocytes. The new astrocytes will release…
Therapeutic Candidate or Device A cell therapy that delivers high levels of neurotrophic factors to the CNS Indication Amyotrophic lateral sclerosis (ALS) or Lou Gehrig Disease Therapeutic Mechanism The Cell…
Therapeutic Candidate or Device CNS10-NPC-GDNF - a neural progenitor cell secreting GDNF Indication ALS Therapeutic Mechanism This therapy will replace damaged astrocytes. The new astrocytes will release paracrine factors. As…
Therapeutic Candidate or Device AS-202, an antisense oligonucleotide Indication Amyotrophic Lateral Sclerosis Therapeutic Mechanism AS-202 targets PIKFYVE, a lipid kinase. By inhibiting PIKFYVE activity, it induces exosomal secretion, which robustly…
This Facebook Live event, "Ask the Stem Cell Team about ALS", aired on July 31st, 2018 and featured a conversation between Drs. Clive Svendsen, Robert Baloh from Cedars-Sinai, Dr. Ralph…
To a stem cell scientist, "Disease in a Dish" describes a powerful way to study human disease in the lab using a Nobel Prize winning technique. But to a non-scientist…
On July 3rd, CIRM hosted a Google Hangout to discuss progress toward stem cell therapies for Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease. Dr. Clive Svendsen, a…
Title: Lumbar Intraspinal Injection of Neural Stem Cells in Patients with ALS: Results of a Phase I Trial in 12 Patients Speaker: Jonathan D. Glass, M.D. Professor, Neurology and Pathology,…
On July 26th 2012, the governing board of California's Stem Cell Agency approved an $18 million Disease Team research grant that aims to bring a stem cell-based ALS treatment to…
CIRM has funded the ALS Disease Team led by scientists at who aim to bring a human embryonic stem cell based ALS therapy to clinical trials within four years. Amyotrophic…
Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
